iAmgenius, the challenge of meeting the needs of cancer patients

Milan, July 9 (AdnKronos Health) – A tumor is not only treated with scalpels and medications. It takes a lot more. And only those who live the path of illness know what it means in practice to deal with visits, exams, checks, daily visits to the hospital. He knows what are the renunciations, the obstacles, the weights to wear, and he knows how many small practical details count, which also escape the clinical eye of the doctors who occupy them. Now, these stories will become a driving force of creativity. Words that will ignite the spirit of young digital talents to create innovative solutions with the ambition to humanize care pathways.
The meeting between these two worlds is the challenge of "iAmgenius", an initiative promoted by Amgen in collaboration with the badociations Garlic (Italian Association Against Leukemia-Lymphoma and Onlus Myeloma) and Europa Donna Italia , the & # 39; pink lobby & # 39; against bad cancer, under the patronage of the Aiom Foundation (Italian Association of Medical Oncology). This starts directly in patients, affected by solid tumors or blood. They will be the ones who will point the way. An online platform has been created to give him a voice (). A space in which, from today until September 30, they will be able to answer a simple question: "What could help you in your daily life?" .
Their suggestions will feed into a "database" from which a jury of experts will select the most appropriate proposals to translate into digital solutions – App and so on – and, in a sort of ideal relay, the witness will pbad in the hands the "brains of Silicon Valley", who will challenge with ideas. The appointment for the latter will be in November in Rome: programmers, developers, web designers, experts in digital health across Italy will face a "marathon" of innovation, a brainstorming of 24 hours that insiders call "hackathon". Led by a mentor and divided into teams, young designers will get to work. At the end of the contest, the jury will reward both innovations, one for patients with solid tumors and the other for patients with blood cancers, which will make the difference more than any other.